Ed Deane

How Phastar Rescued 12 Studies and Became a Long-Term Strategic Partner. Discover how Phastar stepped in to rescue multiple high-stakes oncology trials following quality failures from a previous vendor — restoring data integrity, meeting tight regulatory deadlines, and delivering fully validated outputs. Download the full case study to explore the approach, outcomes, and lasting impact. […]

Delays in patient recruitment can derail even the most well-designed clinical trials. Discover how Phastar’s Recruitment Forecasting app helped a global biopharma company stay ahead of enrolment challenges by using advanced analytics to predict trial completion and optimize patient allocation. Complete the form below to read the full case study

A customer managing a high-profile clinical trial faced significant challenges due to their reliance on Excel for trial monitoring. The process was manual and labor-intensive, and their newly implemented Electronic Data Capture (EDC) system lacked an automatic data extraction module. This made it difficult to manage and analyze data in real time, affecting trial oversight […]

Professor Deborah Ashby, Interim Dean of the Faculty of Medicine, Imperial College, recently presented Phastar’s annual Sally Hollis Memorial Lecture. In this Q&A for Outsourcing Pharma, Professor Ashby and Professor Jennifer Visser-Rogers, Vice-President for Statistical Research and Consultancy at Phastar, discuss how new approaches to clinical trials are changing data monitoring committees. Read the full Q&A at Outsourcing-Pharma.com.

Authors: Giles Partington, Sarah Simpson, Lauren Rojas, Emily Foreman, Ian Wadsworth. Bayesian statistics is one of the two main fields of thought for statistics. Whilst the more familiar frequentist statistics focuses on observing events to attempt to disprove a null hypothesis at a specific p-value and power; Bayesian statistics uses the ideas behind Bayes theorem […]

About this webinar The application of expert prior elicitation in clinical research serves as an important methodological tool to quantify expert knowledge into the definition of prior probability distributions, which can be leveraged to inform Bayesian study design, enhance decision making, and ultimately advance the quality of patient care. In this webinar recording, our panel […]

A great turnout of members from the Phastar family, together with guests from the wider community, gathered in Macclesfield for an evening of education, commemoration, and celebration at the third annual Sally Hollis Memorial Lecture event. This year’s lecture was delivered by Professor Deborah Ashby, Interim Dean of the Faculty of Medicine at Imperial College, […]

Supporting medicine development for disadvantaged communities London, UK, and Durham (NC), US – 26th October 2023: Phastar, a global specialist biometrics contract research organization (CRO) is offering pro bono support to Medicines Development for Global Health (MDGH), a not-for-profit organization developing medicines for neglected diseases primarily affecting people living in low- and middle-income countries. As […]

Author: Professor Deborah Ashby Interim Dean of the Faculty of Medicine, Imperial College London About the lecture  During a clinical trial, accruing data is often seen in confidence by a data monitoring committee to evaluate whether early termination of the study or other modifications are needed in the light of emerging results. For a classical […]

Phastar commits to achieving Net-Zero Standard by 2035 London, UK, and Durham (NC), US – 9th October 2023: Phastar, a global specialist biometrics contract research organization (CRO), has had its net-zero target approved by the Science Based Targets initiative (SBTi). The SBTi is a global body enabling businesses to set ambitious emissions reductions targets in […]

Phastar Sets Course for Further Growth with New CEO Appointment London, UK and Durham (NC), US – 10th August 2023. Phastar, a global specialist biometrics contract research organization (CRO), today announced the appointment of Graham Clark as the new Chief Executive Officer. Amid ambitious growth plans and organizational changes, Clark will succeed Andrew MacGarvey as […]

Author: Stephen Corson | Phastar We are delighted to have made available two slideshow presentations given by Phastar’s Statistics Manager, Stephen Corson, to the statistics and data science community at DIA. Stephen’s presentations are closely related, covering the same material at differing layers of detail and complexity. Both cover key statistical methods, their appropriate applications, […]

Stephen Corson, Statistics Manager at specialist biometrics contract research organization (CRO) Phastar, has been chosen to receive the DIA 2023 Global Inspire Award for Community Engagement. This prestigious award recognises the outstanding contribution of DIA Community Chairs who consistently drive engagement and promote knowledge sharing, while advancing thought leadership within the membership community. Stephen commented: […]

London, UK and Durham, NC – April 13, 2023 – Phastar has supported a Great Ormond Street Hospital-sponsored study into new treatments for children with severe combined immunodeficiency (SCID). The company provided pro bono support from its specialist statisticians, data managers and programmers for the study, testing efficacy and safety of cryopreserved haematopoietic stem cells […]

London, UK and Durham, NC – January 10, 2023 – Phastar announced today the acquisition of S-Cubed ApS, a specialist biometrics and data visualisation company. The deal takes the Phastar group to around 550 people worldwide and strengthens the company’s position in the Nordic region. Andrew MacGarvey, CEO of Phastar, commented, “I am pleased we […]

This project was a collaboration between Kopenhagen Konsulting and Phastar Denmark. KK Management Konsulting lead the project and report/metric definitions. Phastar Denmark developed and implemented the technical solution. They wanted to automate the process of pulling data reports from multiple systems, calculate various metrics, and create automated visualizations of the figures on a monthly basis. […]

London, UK and Durham, NC – 08 December, 2022 – Phastar, a global specialist biometrics contract research organization (CRO), has joined Lean Life Science’s Oncology Development Programme (ODP2). The targeted programme aims to identify and accelerate novel oncology innovations into commercially-attractive assets by offering support to academics and early-stage companies. In collaboration with top global […]

New pro-bono scheme allows charities to access Phastar’s biometrics experts at no cost London, UK and Durham, NC – November 5, 2022 – Phastar, a global specialist biometrics contract research organization (CRO), has announced the launch of a pro-bono scheme to give charities access to its volunteer statisticians, data scientists, data managers and programmers at […]

The experience across the team at Phastar is rich and varied and on average the technical team has over 14 years’ experience, which is a wealth of knowledge that brings huge benefits to our clients. The team are not only experts working with data but also the analytics of that data to deliver value. The […]

Beijing, China and London, UK, April 20, 2022 – Phastar, a global specialist biometrics contract research organization (CRO) offering industry leading data management, data science, statistical consulting, and clinical trial reporting services, today announces that Ping-Chung Chang has joined the company as Head of China Development and Global Delivery. Ping brings deep experience in CRO […]

Presented by: Professor James Carpenter | MRC Clinical Trials Unit, LSHTM Complete the form below to watch the webinar

Hepatitis B virus (HBV) infection is among the most common persistent viral infections in humans. Chronic infection of HBV (CHB) can lead to serious medical complications such as cirrhosis, hepatocellular carcinoma, and liver failure. Surrogate markers are often used to monitor the progression of the disease and patients are treated with antiviral agents to reduce […]

A new formulation under investigation was planned to be submitted for use in both the US and Europe. As the reference formulation in the US differs from that in Europe, two separate bioequivalence studies were needed to gain approval from the FDA and EMA. Study 1 was conducted for FDA approval and successfully demonstrated bioequivalence. […]

London, UK and Durham, NC – 3 August 2021 – Phastar, a global specialist biometrics contract research organization offering industry leading data management, data science, statistical consulting and clinical trial reporting services, announced today the appointment of Chuck Gelb as Chief Commercial Officer. Holding an MBA in Pharmaceutical Management and an MA in Biotechnology, Chuck […]

Phastar was awarded as a preferred supplier to a top 20 pharmaceutical sponsor, supporting five new studies per year. Each study was several years in length, with IDMC meetings taking place every 3-6 months. Phastar worked with this pharmaceutical sponsor through two models for IDAC support; model one offering independent programming of the blinded and […]

Presented by: LaRee Tracy, PhD, and Joshua Baker, PhD Complete the form below to watch the webinar

Presented by: Jordan Bristow | Phastar Complete the form below to watch the webinar

Presented by: Lucy McParland | Phastar Complete the form below to watch the webinar

Presented by: Kirsty Millar | Phastar Complete the form below to watch the webinar

Phastar was contracted to assist a global pharmaceutical company with their integrated summary of safety and efficacy for a regulatory submission. The work started with assisting the sponsor in defining an integration strategy for approximately 20 phase I studies, six phase II studies and their corresponding extension as well as three phase III studies and […]

Phastar has a number of sponsor relationships where we provide teams of statisticians and statistical programmers to complement the internal teams within medium and large pharma companies. For example, we provide a large integrated production team of statisticians and statistical programmers to a large global pharmaceutical company. The Phastar staff primarily work from our offices […]

Tokyo, Japan and London, UK – 23rd June 2020 –Phastar, a global CRO offering industry leading statistical consulting, clinical trial reporting, data management and data science services, announced today that the company has officially opened its Tokyo office. Phastar Tokyo will serve as a strategic operational hub to support our Japanese partners and is a […]

Durham, NC and London, UK – December 4, 2019 – Phastar, a global CRO, has gained its 2020 Star rating based on the Best Companies’ Index score. Best Companies is a UK organization which sets accreditation standards for workplace engagement. PHASTAR’s score was derived from a survey conducted by Best Companies, which sets awards based […]

London, UK and Cambridge, MA – June 24, 2019 – Phastar announced today that it has entered into a technology partnership with Medidata Solutions, Inc.. Phastar will deploy several solutions from the Medidata Rave Clinical CloudTM including Rave EDC, Coder, eCOA, and RTSM. The adoption of the Medidata Rave Clinical Cloud comes as Phastar continues […]

London, UK and Cambridge, MA – June 21, 2019 – Phastar, a global CRO, announced today that it will establish new offices in Tokyo and West Coast, US in 2020. Recruitment has already started for staff in the new offices which will serve as operational hubs for customers in Japan and the West Coast of […]

Phastar is delighted to be announced today as winners of the highly coveted Queens Award for Enterprise, in the International Trade category! Phastar’s win was down to its excellence in international trade and its exponential growth from a one-person operation in 2007, to a global CRO with offices in four continents within the space of […]

On Tuesday 24th July 2018, Phastar presented a webinar on the topic ‘Efficiencies when delivering a quality database’. The presenters were Sheelagh Aird, Head of Clinical Data Operations and Gillian Childs, Principal Data Coordinator. The webinar, hosted by X-talks and Medrio, demonstrated the importance of controlling the quality of a database right from study set-up. […]

London, UK and Durham, NC – January 5 2021 – Phastar, a specialist biometrics clinical research organization (CRO) for clinical trials, announces an investment made by Charterhouse Capital Partners LLP, a long-established European private equity firm, which will support Phastar’s growth in biometrics and geographic expansion. Charterhouse is making its investment in partnership with PHASTAR’s […]

Phastar is delighted to have been shortlisted for the 2018 SCRIP Award in the category: Best Contract Research Organization – Specialist Provider. For the third year in succession, Phastar has been recognised for its success in delivering high quality statistical consulting, clinical trial reporting and data management. Now in its 14th year, the Scrip Awards […]

Data managers strive to produce high quality, reliable and intact data for analysis. Integral to this quality standard is to ensure minimal or no missing data. Missing data may have different sources such as equipment failure, missed visits, death or withdrawal of a subject and is usually dealt with during the analysis by defined handling […]

Special consideration needs to be given to providing data for interim locks and DSMBs during the course of a study. It is crucial that the data provided for these milestones is as complete, accurate and up-to-date as possible because the outcome can have serious implications on the review and progress of the study.  It is […]

Phastar ranks inside the FT 1000! Recognising Phastar’s continued success, the company has recently been included as one of this year’s Europe’s 1000 Fastest Growing Companies. Phastar was featured in the Financial Times supplement on 7th April 2017 (see here) once again acknowledging Phastar’s accomplishments over recent years, growing into a successful provider of statistical […]

A key issue in assessing the efficacy of new drugs in oncology is getting the balance right between choosing a hard endpoint survival – and an endpoint that allows evidence to be assessed more quickly progression. Often discussions such as these are required after interactions with regulatory agencies. Progression free survival is used in many […]

Oncology trials are complex and require a different approach to trials compared with many other therapeutic areas and can generate significant programming challenges. Oncology can be associated with fast developing disease and short survival times. Due to the fact that many oncology trials are event-driven, the timelines and resources are regularly reviewed and updated. In […]